Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies

By /

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.

Scroll to Top